Ipsen – Half year statement – 2024 12 31
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Boulogne-Billancourt (France), January 7th, 2025 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2024, the following resources were included to the dedicated liquidity account:
- 24,701 shares
- €2,635,980.25
It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account:
- 12,751 shares
- €3,137,934.80
Between July 1st, 2024 and December 31st, 2024 have been executed:
- 2,936 purchase transactions
- 2,346 sell transactions
Under the same period, the volumes traded represented:
- 311,792 shares and €33,997,824.80 to the purchase
- 321,682 shares and €35,215,771.10 to the sel
Attachment

Ipsen – Half year statement – 2024 12 31
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Boulogne-Billancourt (France), January 7th, 2025 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2024, the following resources were included to the dedicated liquidity account:
- 24,701 shares
- €2,635,980.25
It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account:
- 12,751 shares
- €3,137,934.80
Between July 1st, 2024 and December 31st, 2024 have been executed:
- 2,936 purchase transactions
- 2,346 sell transactions
Under the same period, the volumes traded represented:
- 311,792 shares and €33,997,824.80 to the purchase
- 321,682 shares and €35,215,771.10 to the sel
Attachment

Related stories
Quand les acides biliaires prennent une dimension plus large : comment la biologie de la cholestase transforme la recherche sur les maladies hépatiques rares
Tester l’hypothèse : un pilote ciblé sur l’IA dans le domaine de la santé
Toujours une longueur d’avance : Anne Petit et l’art de concrétiser les médicaments
Related Press Releases
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset...
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen – June 2026 – Monthly information relative to the...
Ipsen – Half year statement – 2026 06 30
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus...
Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
IPSEN – Buy-back programme – Art 5 of MAR –...